Physician profile
Benjamin Barnes
NPI 1760866545
$50,084.77
in general payments reported to CMS, 2019-2025
46 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 93% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.40 · 2020: $1,618 · 2021: $7,511 · 2022: $29K · 2023: $7,853 · 2024: $1,974 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,662 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,080 · Travel and Lodging: $1,081 · Consulting Fee: $102 · Education: $24.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,661.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,080.00 |
| Travel and Lodging | $1,081.00 |
| Consulting Fee | $102.00 |
| Education | $24.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $38,285.39 | 2020-2025 | Spinraza, Skyclarys, Spinraza |
| Argenx US, INC. | $4,246.84 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $1,389.53 | 2019-2025 | Ultomiris, Soliris |
| Tanabe Pharma America, INC. | $726.22 | 2021-2025 | Radicava |
| Abbvie INC. | $662.07 | 2022-2025 | Ubrelvy, Botox, Qulipta |
| Ucb, INC. | $529.20 | 2023-2025 | Rystiggo, Zilbrysq, Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $417.65 | 2022-2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $417.08 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $396.70 | 2022-2025 | Ingrezza, Ongentys |
| Ipsen Biopharmaceuticals, INC | $276.79 | 2022-2025 | Dysport |
| Csl Behring | $275.41 | 2023-2025 | Hizentra |
| Pfizer INC. | $246.06 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $191.67 | 2021-2025 | Xeomin, Inbrija |
| Alnylam Pharmaceuticals INC. | $186.77 | 2023-2025 | Amvuttra, Onpattro |
| Amylyx Pharmaceuticals, INC. | $174.11 | 2023 | Relyvrio |
Show all 44 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.